<DOC>
	<DOC>NCT02366637</DOC>
	<brief_summary>This study proposes to evaluate the safety and efficacy of PF-03715455 in subjects with moderate to severe Chronic Obstructive Pulmonary Disorder.</brief_summary>
	<brief_title>An Evaluation Of PF-03715455 In Moderate To Severe Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Female subjects of nonchildbearing potential and male subjects between the ages of 40 and 80 years, inclusive Subjects with a diagnosis, for at least 6 months, of moderate to severe COPD and who meet the criteria for Stage IIIII disease Subjects must have a smoking history of at least 10 packyears Current evidence or history within the previous 6 months of any clinically significant disease (other than COPD) or abnormality in the opinion of the Investigator that would put the subject at risk or which would compromise the quality of the study data A COPD exacerbation requiring treatment with oral steroids or hospitalization for the treatment of COPD within 3 months of Screening</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>Sputum</keyword>
</DOC>